Carcinoid Syndrome - 25 Studies Found
| Completed |
: Study of LX1606 in Subjects With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy : Carcinoid Syndrome : 2009-02-25 :
|
| Completed |
: A Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of Carcinoid Syndrome Associated With Episodes of Diarrhea :
: 2010-10-20 |
| Completed |
: An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in Males : Carcinoid Syndrome : 2013-08-27 : Drug: 500 mg [14C]-LX1606 500 mg dose of LX1606 containing a target dose of 3.32 Megabecquerel (MBq) of |
| Terminated |
: P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome : Neuroendocrine Carcinoma : 2013-06-21 : Drug: Octreotide LAR Octreotide LAR as outlined in Treatment Arm. |
| Completed |
: Azilect + Antidepressant Chart Review : Serotonin Syndrome : 2009-08-06 :
|
| Completed |
: Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor :
: 2006-12-13 :
|
| Completed |
: Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid Tumors :
: 1999-11-01 :
|
| Completed |
: Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors : Carcinoid Tumors : 2004-07-30 : Drug: Pasireotide (SOM230) Open label. Patients received starting dose of 300 µg of study drug subc |
| Withdrawn |
: Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors :
: 2005-09-26 :
|
| Active, not recruiting |
: Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors :
|